secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2026-10-02T12:05:48+00:00
Accession:  0001193125-26-411298
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Surrozen wins FDA clearance for SZN-8141 IND; $95.1M second closing milestone triggered
--------------------------------------------------------------------------------

- FDA cleared Surrozen's IND for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody given as an intravitreal injection for diabetic macular edema (DME).
- First patient dosing in the Phase 1b/2a DUET study in DME expected in Q4 2026, with initial data expected in the second half of 2027.
- IND clearance satisfies the second closing milestone of the March 2025 two-tranche private placement; ~$95.1M in gross proceeds expected on or about October 20, 2026.
- Proceeds will support SZN-8141, SZN-8143 and broader operations; an S-3 resale registration must be filed within 30 days of closing.
- Surrozen also plans to develop SZN-8141 in neovascular age-related macular degeneration and is evaluating other retinal vascular diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/0001193125-26-411298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/srzn-20261002.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-411298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer